Alpine Immune Sciences downgraded to Peer Perform at Wolfe Research

Wolfe Research analyst Andy Chen downgraded Alpine Immune Sciences (ALPN) to Peer Perform from Outperform after the announcement that the company agreed to an acquisition by Vertex (VRTX). In light of the announced deal, the firm expects “limited fluctuations in price” of Alpine shares until the acquisition is complete, the analyst tells investors.